ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2465

CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study

(2437–2469) Systemic Lupus Erythematosus – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2073

Cell-free DNA as a Potential Marker of Muscle Involvement and Treatment Response in Myositis

(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 1852

Cellular Landscape of Cutaneous Lupus Erythematosus Revealed by Single-Cell RNA Sequencing and Spatial Transcriptomics in the Lupus Accelerating Medicine Partnership Cohort

(1830–1854) Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 1897

Changes in SLE Mortality During and After the COVID-19 Pandemic

(1877–1913) Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2210

Changes in Treatment Pathways Over Time in Pregnancies with Active Lupus Nephritis

(2195–2226) Reproductive Issues in Rheumatic Disorders Posters

10:30AM-12:30PM: Abstract Number: 2280

Changes of B Cell Subsets During Treatment with Abatacept in Patients with Rheumatoid Arthritis

(2265–2289) Rheumatoid Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2004

Characteristics and Management of Gout Patients Under Rheumatologist Care from Low-Income and Middle-Income Asia-Pacific Countries: Data from the APLAR Gout Registry

(1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2029

Characteristics of a Historical Cohort of Adult Patients with Juvenile Idiopathic Arthritis

(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2001

Characteristics of Gout Flares Over Time with Treat-to-Target Urate-Lowering Therapy Use

(1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2070

Characterization of Hospitalization, Patient Demographics and Impact of Idiopathic Inflammatory Myopathies on Hospitalization Outcomes in Adult Fracture Patients: A National Inpatient Sample Analysis.

(2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 1999

Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials

(1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2482

Characterizing Gastrointestinal Involvement in Systemic Sclerosis: Insights from the National Systemic sclerosis Progression INvestiGation (SPRING) Registry of the Italian Society of Rheumatology

(2470–2503) Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1911

Characterizing Psoriasis Patients at Risk for Transition to Psoriatic Arthritis: Early Insights from the STOP PsA At-Risk Cohort

(1877–1913) Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 1917

Characterizing the Frequency and Timing of Changes in Patient-Reported Social Risk Factors among Rheumatology Outpatients

(1914–1935) Health Services Research Poster III

10:30AM-12:30PM: Abstract Number: 2354

ChatGPT or SPSS? A comparison between AI-based and Traditional Statistical Analysis of Longitudinal Inflammatory Marker Data in Spondyloarthritis

(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

«Previous Page
1
…
8
9
10
11
12
…
62
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].